Driven by the perspective of maximizing shareholder value (MSV), the U.S. biopharmaceutical industry has adopted a highly financialized business model. In such a model, the key metrics are stock-price performance, earnings per share, and dividend yield, supported by distributions to shareholders in the forms of dividends and stock buybacks. Such value extraction is incentivized by […]
![Innovation vs Financialization: an Analysis on the United States as a Source of Innovation for European Big Pharma working_paper_2017_17_cover](http://www.isigrowth.eu/wp-content/uploads/2017/06/working_paper_2017_17_cover-100x100.jpg)